Background: Raphanus sativus is reported to have a variety of biological activities. This work screened the hepato-protective and antioxidant activity of ethanol (ERS), and aqueous (ARS), extracts of leaves of Raphanus sativus in Carbon tetrachloride (CCl 4 ), model in rats. Material and Methods: The extracts were subjected to antioxidant tests (Total reducing power and Total phenolic content), and preliminary phytochemical screening. A pilot study was done on 100 and 300 mg/kg extracts, form which 300 mg was chosen for further experiments. The albino rats (200-250 grams), were divided into 5 groups of 6 animals each (n=6). There were three control groups comprising of normal control (normal saline -1ml/kg), negative control group (CCl 4 1ml/kg in olive oil in a ratio of 1:1 v/v), and positive control group (Silymarin 50mg/kg). The Test drugs were given in a dose of 300 mg/kg for both ERS and ARS extract for 7 days. Biochemical parameters (AST, ALT, Alkaline phosphatase, Total Bilirubin), histo-pathological examination of liver and in vivo antioxidant tests [CAT, GSH and MDA] were done. Results: The phytochemical study showed the presence of flavanoids, terpenoids, alkaloids, saponins and sterols. A dose dependent increase in the oxidative potential was observed in both the extracts with total phenolic content 70.1 and 44.4 GAE/g extract for ERS and ARS respectively. ERS 300mg/kg showed a significant (p<0.001) increase in levels of AST, ALT and alkaline phosphatase as compared to negative control (percentage hepatoprotection =45.3%) while ARS 300 mg/kg (p<.01) group showed 30% hepatoprotection. The GSH (p<0.001) and CAT (p<0.05) in ERS and ARS were significantly increased while MDA levels were decreased (P< 0.01), as compared negative control. The findings were confirmed histo-pathological examination. Conclusion:The ethanol and aqueous extract of Raphanus sativus have partial hepatoprotection against CCl 4 toxicity.

Present study indicates that nerves of lower limbs are more susceptible to diabetic assault as compared to upper limb suggesting that long nerves are commonly affected. Also, apart from duration and severity of diabetes, smoking itself is an independent factor for diabetic neuropathy.

No abstract

their folklore claim in the book by Hakim Abdul Wahid (1961) 1 and experimented for potential hepatoprotection in albino rats. It is known as "Tagar" in Hindi and Indian Valerian in English. METHODS The roots of Valariana wellichi was purchased from local herbal dealer. It was identified & authenticated by botanist and a voucher specimen was submitted ABSTRACT Background: Drugs for liver ailments have been important in research, but still the number of drugs acting on various hepatic diseases is very limited. This study, for the fi rst time, evaluates the hepatoprotective activity of aqueous extract of the roots of Valeriana Wallichii in albino rats. Methods: The hepatotoxicity was induced by CCl 4. Animals were divided into 5 groups of 6 animals each. Group I (Normal control) was given only distilled water. Group II (Negative control)was administered CCl 4 for 7 days while Group III (Positive control) was given silymarin and CCl 4 for 7 days. The test groups (Group IV & V) were given an aqueous extract of roots of V. Wallichii in a dose of 300 mg and 500 mg/kg, respectively. The animals were sacrifi ced on 8 days and blood was collected for biochemical analysis (aspartate aminotransferase [AST], alanine transaminase (ALT) and alkaline phosphatase). Liver tissue was extracted for histopathological examination and in vivo antioxidant tests Catalase [CAT], glutathione and malondialdehyde. The extract was also subjected to in vitro antioxidant tests (Total reducing power and total phenolic content). Results: The test extracts in the dose of 500 mg/kg were shown a signifi cant decrease in the levels of AST and ALT (p>0.05) and CAT activity. 300 mg/kg dose of extract showed minimal hepatoprotection. The fi ndings were confi rmatory to histopathology. Conclusion: The aqueous extract of roots of V. Wallichii in a dose of 500 mg/kg offers partial protection against hepatotoxicity produced by CCl 4 in albino rats.

Background Non-alcoholic fatty liver disease (NAFLD) also referred as metabolic as metabolic (dysfunction) associated fatty liver disease. Type 2 diabetes mellitus (T2DM) is a major cause in progression of NAFLD and non-alcoholic steatohepatitis (NASH). The aim of the present study is to assess the activity of liver enzymes in T2DM in North Indian population. Method This was a cross-sectional descriptive study clinic-based study in patients with T2DM. A total of 612 participants (226 healthy controls and 386 T2DM) were recruited. Body mass index (BMI), activity of liver enzymes including alanine and aspartate aminotransferase (ALT, AST) along with alkaline phosphatase (ALP) was measured. Fasting blood glucose (FBG) and glycosylated hemoglobin (HbA1c) along with total protein (TP) and albumin were also measured. Quantitative variables were expressed as mean ± SD, while qualitative variables as frequencies (%). Pearson/Spearman correlation test, unpaired t -test, Chi-squared test was used to assess the correlation, association and significant differences between study groups respectively. A P-value of < .05 was set as statistically significant. The Statistical Package for Social Sciences (SPSS) ® Statistics, version 23 (IBM SPSS Statistics, Armonk, NY) was used to for analysis of data. Results The study was conducted on 386 T2DM patients, and out of 386 patients, 139 (36.01%) were male (P < .000) and 247 (63.98%) were female. The mean age of the T2DM patients was 46.4 ± 13.6 years, while healthy individuals have mean age of 39.2 ± 12.0 years (P < .000). It was observed that the activity of AST in T2DM is comparable with the healthy persons (P = .060). While the level of ALT, total bilirubin and ALP in T2DM is significantly higher compared to healthy control (P < .000). On average, 62.53% of T2DM subjects and 32% of participants of healthy subjects had abnormal liver enzymes activity. Conclusion The present study has revealed widely co-existent derangements in liver function tests (LFTs) in the diabetic population of North India. A detailed workup in such patients may be helpful in timely diagnosis and treatment. Moreover, early detection and management of abnormal liver parameters in T2DM would help minimize liver-related morbidity and mortality.